Home Cart 0 Sign in  

[ CAS No. 136572-09-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 136572-09-3
Chemical Structure| 136572-09-3
Structure of 136572-09-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 136572-09-3 ]

Related Doc. of [ 136572-09-3 ]

Alternatived Products of [ 136572-09-3 ]

Product Details of [ 136572-09-3 ]

CAS No. :136572-09-3 MDL No. :MFCD01765731
Formula : C33H45ClN4O9 Boiling Point : -
Linear Structure Formula :- InChI Key :KLEAIHJJLUAXIQ-JDRGBKBRSA-N
M.W : 677.18 Pubchem ID :60837
Synonyms :
CPT-11 hydrochloride trihydrate;Irinotecan (hydrochloride hydrate);CPT-11 HCl Trihydrate;Irinotecan HCl Trihydrate;(+)-Irinotecan hydrochloride trihydrate
Chemical Name :(S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride trihydrate

Calculated chemistry of [ 136572-09-3 ]

Physicochemical Properties

Num. heavy atoms : 47
Num. arom. heavy atoms : 16
Fraction Csp3 : 0.52
Num. rotatable bonds : 6
Num. H-bond acceptors : 11.0
Num. H-bond donors : 4.0
Molar Refractivity : 185.74
TPSA : 141.89 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -8.22 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 3.12
Log Po/w (WLOGP) : 3.68
Log Po/w (MLOGP) : 0.47
Log Po/w (SILICOS-IT) : 4.33
Consensus Log Po/w : 2.32

Druglikeness

Lipinski : 2.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 2.0
Bioavailability Score : 0.17

Water Solubility

Log S (ESOL) : -5.86
Solubility : 0.000935 mg/ml ; 0.00000138 mol/l
Class : Moderately soluble
Log S (Ali) : -5.77
Solubility : 0.00115 mg/ml ; 0.0000017 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -7.28
Solubility : 0.0000356 mg/ml ; 0.0000000526 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 6.05

Safety of [ 136572-09-3 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P501-P270-P264-P301+P310+P330-P405 UN#:2811
Hazard Statements:H301 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 136572-09-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 136572-09-3 ]
  • Downstream synthetic route of [ 136572-09-3 ]

[ 136572-09-3 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 100286-90-6 ]
  • [ 136572-09-3 ]
YieldReaction ConditionsOperation in experiment
87% With hydrogenchloride; water In ethanol at 75 - 80℃; Irinotecan HCl (4.8 g), water (30 ml), ethanol (10 ml) and 5 percent HCl (0.3 ml) were charged. The mixture was heated to 75-80 °C and stirred until all dissolved. The solution was cooled to 65 0C and seed crystals were added. The solution was cooled in 10 hours to 50 °C and in 10 hours to 20 0C. The crystalline compound was filtered and washed with water ( 16 ml) .The product was dried under normal pressure at room temperature.The yield of irinotecan HCl 3H2O was 4.6 g (87 percent).The HPLC-purity was 99.9 percent. Based on X-ray and IR analysis the product is form b as defined in WO 03/074527. The average length of the crystals was 50 μm -200 μm by microscopic analysis.
Reference: [1] Patent: WO2006/84941, 2006, A2, . Location in patent: Page/Page column 6
[2] Patent: WO2006/84941, 2006, A2, . Location in patent: Page/Page column 5-6
Same Skeleton Products
Historical Records